Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience

Attal, 2017, Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma, N Engl J Med, 376, 1311, 10.1056/NEJMoa1611750 Bahlis, 2020, Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study, Leukemia, 34, 1875, 10.1038/s41375-020-0711-6 Giralt, 2015, Biol Blood Marrow Transplant, 21, 2039, 10.1016/j.bbmt.2015.09.016 Kumar, 2020, Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 18, 1685, 10.6004/jnccn.2020.0057 Tricot, 1995, Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy, Bone Marrow Transplant, 16, 7 Olin, 2009, Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma, Bone Marrow Transplant, 43, 417, 10.1038/bmt.2008.334 Alvares, 2006, The role of second autografts in the management of myeloma at first relapse, Haematologica, 91, 141 Hagen, 2019, The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma, Biol Blood Marrow Transplant, 25, e98, 10.1016/j.bbmt.2018.12.002 Cook, 2016, Lancet Haematol, 3, e340, 10.1016/S2352-3026(16)30049-7 Cook, 2011, Biol Blood Marrow Transplant, 17, 1638, 10.1016/j.bbmt.2011.04.005 Durie, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U Chng, 2014, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma, Leukemia, 28, 269, 10.1038/leu.2013.247 Rajkumar, 2015, Guidelines for determination of the number of prior lines of therapy in multiple myeloma, Blood, 126, 921, 10.1182/blood-2015-05-647636 Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 17, e328, 10.1016/S1470-2045(16)30206-6 Mikhael, 2007, Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relased multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT, Blood, 110 Simpson, 2007, Outcome after second stem cell transplantation for relapsed multiple myeloma, J Clin Oncol, 25 Sonneveld, 2016, Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood, 127, 2955, 10.1182/blood-2016-01-631200 Hari, 2020, Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM), J Clin Oncol, 38, 8506, 10.1200/JCO.2020.38.15_suppl.8506 Barlogie, 1999, Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, 93, 55, 10.1182/blood.V93.1.55 Attal, 2003, Single versus double autologous stem-cell transplantation for multiple myeloma, N Engl J Med, 349, 2495, 10.1056/NEJMoa032290